Company intelligence / Profile preview

Changsha Aibeigao Pharmaceutical

Changsha, Hunan, China

Ownership: Private
Development stage: Other

Overview

Changsha Aibeigao Pharmaceutical is a Chinese pharmaceutical company specializing in the development and commercialization of pediatric and endocrine treatments, with a primary focus on growth hormone therapies. The company is best known for its involvement in the production and distribution of recombinant human growth hormone (rhGH) products designed to treat growth hormone deficiency and related conditions in children. Based in Changsha, Hunan Province, the firm operates within the high-tech medical sector, integrating research, development, and sales. Its product portfolio aims to address unmet needs in the domestic Chinese market for pediatric endocrinology.

Therapeutic areas: EndocrinologyRare Diseases
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Changsha Aibeigao Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changsha Aibeigao Pharmaceutical.

Explore the full profile